- Home
- CRBP vs SLMT Comparison
CRBP vs SLMT Comparison
Compare CRBP & SLMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBP | SLMT |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 170.9M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRBP | SLMT |
|---|---|---|
| Price | $10.10 | $0.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $45.60 | N/A |
| AVG Volume (30 Days) | 201.7K | ★ 772.7K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $4.64 | $0.68 |
| 52 Week High | $20.56 | $24.05 |
Technical Indicators
Market Signals| Indicator | CRBP | SLMT |
|---|---|---|
| Relative Strength Index (RSI) | 62.24 | 41.65 |
| Support Level | $9.86 | N/A |
| Resistance Level | $11.64 | $1.41 |
| Average True Range (ATR) | 0.69 | 0.10 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 83.54 | 35.51 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About SLMT Brera Holdings PLC Class B Ordinary Shares
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.